Alemtuzumab
How it works: Resetting the immune system →
Lemtrada
EU: Approved in the EU since 2013US: FDA approved 2001
FDA dates refer to the first approval of the product's licence. For alemtuzumab and ofatumumab this was an earlier cancer approval.
- Molecule type
- Antibody
- Mechanism (ChEMBL)
- CAMPATH-1 antigen inhibitor
- Targets
- CAMPATH-1 antigen
- Availability
- Authorised in all EU and EEA countries. Reimbursement is decided by each country.
Approvals
Safety communications
- EMA referral (safety) · 11 April 2019
Lemtrada Source
Most-reported side effects (FDA reports)
Reports to the FDA's adverse event system (FAERS) show what people and doctors reported while taking the medicine. They do not prove the medicine caused it, and they are not rates.
19,551 reports in total, 16,841 marked serious.
- Headache1,906
- Fatigue1,877
- Pyrexia1,800
- Off label use1,702
- Rash1,204
- Nausea1,192
- Drug ineffective1,038
- Dyspnoea993
- Asthenia945
- Multiple sclerosis relapse923
Trials
Key trials
Large trials with a reported result on their main goal.
- Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, S
Completed · Phase 3 · Relapsing MS · Met its main goal
- Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, S
Completed · Phase 3 · Relapsing MS · Met its main goal
Running now
- A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY
Running, not recruiting · Relapsing MS · Still running
- Determining the Effectiveness of earLy Intensive Versus Escalation App
Running, not recruiting · Phase 4 · Relapsing MS · Still running
Other trials (26)
Completed small trials, dose-finding studies and trials in other diseases.
- ADAs to Alemtuzumab
Completed · Relapsing MS · No results found
- Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsin
Completed · Phase 4 · Relapsing MS · Results posted, not judged
- A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab
Terminated · Phase 3 · Relapsing MS · Stopped
- Neurofilaments for NEDA Assessing in MS
Terminated · Relapsing MS · Stopped
- Physical and Cognitive Performance During the Two First Years of Lemtr
Completed · MS (type not specified) · Paper found, not read
- Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers
Status unknown · MS (type not specified) · Paper found, not read
- The Effect of Alemtuzumab on the Blood-brain-barrier and the Brain's M
Status unknown · Relapsing MS · No results found
- Observational Study of a Novel Peri Infusion Regimen on the Infusion A
Completed · MS (type not specified) · No results found
- The Effectiveness of an Additional Course of Alemtuzumab in Relapsing
Completed · Phase 3 · Relapsing MS · No results found
- A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Pat
Completed · Phase 1 · Progressive MS · Paper found, not read
Trials where it is given as background therapy
- Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab T
Terminated · Phase 1 / Phase 2 · MS (type not specified) · Stopped
For information only, not medical advice. Talk to your neurologist before changing treatment.
Hypotheses involving this medicine
Loading hypotheses…
Loading reviews and guidelines…
Lab studies
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…